title: Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8.
abstract: Certain effects of melatonin on senescence were investigated. The experimental model used was 10-month-old senescence-accelerated mouse prone 8 (SAMP8). The mice in the experiment were administered melatonin (10 mg/kg) from the age of 1 month. Results showed that chronic administration of melatonin decreased cell loss in the cerebral cortex and reduced oxidative damage in protein and lipids. There are several studies suggesting that the activation of the cdk5/p35 pathway at its cleavage to cdk5/p25 may play a role in hyperphosphorylation of tau during aging and neurodegenerative diseases. Melatonin not only reduced the cerebral aging disturbances, but also prevented tau hyperphosphorylation present in the experimental model used in this study. Melatonin reduced cdk5 expression, as well as the cleavage of p35 to p25. The other tau kinase studied, GSK3beta, showed a reduction in this activity in comparison with SAMP8 nontreated SAMP8. These data indicate that melatonin possesses neuroprotective properties against cerebral damage gated to senescence. Moreover, these data suggest that the cdk5/GSKbeta signaling cascade has a potential role as a target for neurodegenerative diseases related to aging.
authors: Unitat de Farmacologia i Farmacognòsia, Facultat de Farmàcia and Institut de Biomedicina, Universitat de Barcelona, Nucli Universitari de Pedralbes, Barcelona, Spain.
authors: Javier
authors: J
authors: Gutierrez-Cuesta
authors: Francesc X
authors: FX
authors: Sureda
authors: Marta
authors: M
authors: Romeu
authors: Anna M
authors: AM
authors: Canudas
authors: Beatriz
authors: B
authors: Caballero
authors: Ana
authors: A
authors: Coto-Montes
authors: Antoni
authors: A
authors: Camins
authors: Mercè
authors: M
authors: Pallàs
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D020208:Brain Injury, Chronic / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D002374:Catalase / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051360:Cyclin-Dependent Kinase 5 / Q000378:metabolism; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008550:Melatonin / Q000008:administration & dosage*; D051379:Mice; D008818:Mice, Neurologic Mutants; D009419:Nerve Tissue Proteins / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010766:Phosphorylation; D010770:Phosphotransferases / Q000378:metabolism
chemical_list: D015415:Biomarkers; C492236:Cdk5r1 protein, mouse; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D002374:Catalase; D010770:Phosphotransferases; D051360:Cyclin-Dependent Kinase 5; D000071679:Glycogen Synthase Kinase 3 beta; C000605507:Gsk3b protein, mouse; C495906:Cdk5 protein, mouse; D038362:Glycogen Synthase Kinase 3; D008550:Melatonin